[Thyroglobulin - An important tumor marker and laboratory challenge].

Area of Science:

• Endocrinology
• Oncology
• Clinical Chemistry

Background:

• Differentiated thyroid cancer (DTC) management involves postoperative monitoring.
• Serum/plasma thyroglobulin (TG) and neck ultrasonography are standard monitoring tools.
• Thyroglobulin (TG) serves as a tumor marker in DTC patients on levothyroxine therapy.

Purpose of the Study:

• To evaluate the reliability of serum thyroglobulin (TG) testing in differentiated thyroid cancer (DTC) follow-up.
• To address challenges in accurate TG determination due to interfering variables.
• To explore alternative methods for TG measurement in cases of inconclusive results.

Main Methods:

• Review of current practices for postoperative monitoring in DTC.
• Analysis of common methods for confirming TG test results, including TG recovery rate and anti-TG autoantibody (TGAb) determination.
• Consideration of heterophilic antibody interference.
• Discussion of mass spectroscopic TG determination as an alternative.

Main Results:

• Standard immunologic TG determination requires confirmation to mitigate interfering variables.
• TG recovery rate and TGAb determination are common but imperfect confirmation methods.
• Heterophilic antibodies represent a significant source of interference in TG assays.
• Mass spectroscopic TG determination offers a more complex but potentially definitive alternative.

Conclusions:

• Accurate thyroglobulin (TG) measurement is critical for effective differentiated thyroid cancer (DTC) monitoring.
• Existing methods for confirming TG results have limitations in addressing all interfering variables.
• Mass spectrometry provides a more robust approach for TG determination in complex clinical scenarios.